Eisai to launch Alzheimer’s disease drug Leqembi in Japan 20 Dec
Eisai said its Alzheimer’s disease drug Leqembi will go on sale in Japan on 20 December after being included in the national health insurance price list. Intravenous treatment with the drug, developed with U.S. partner Biogen, will cost about 2.98 million yen (US$20,438) per patient per year, according to a Japanese health ministry panel ruling the same day.
POPULAR POSTS
‘The Kardashians’ renewed by Hulu for 20 more episodes
July 26, 2024
Death toll from landslides in Ethiopia could rise to 500
July 26, 2024
The Canadian wildfire has made its way to Jasper
July 26, 2024
LIVE STREAM